Hull and East Yorkshire Hospitals NHS Trust

THE NOX1/4 INHIBITOR GKT831 ACHIEVES CLINICALLY MEANINGFUL REDUCTIONS IN LIVER STIFFNESS, ATTENUATES CHOLESTASIS, AND IMPROVES QUALITY OF LIFE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (2019) Huang JC, Invernizzi P, Dalekos GN, Nevens F, Van Vlierberghe H, Zigmond E, Andrade RJ, et al. Conference contribution Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial (2019) Dalekos G, Invernizzi P, Nevens F, Hans VV, Zigmond E, Andrade RJ, Ben Ari Z, et al. Conference contribution Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology (2019) Went M, Sud A, Speedy H, Sunter NJ, Foersti A, Law PJ, Johnson DC, et al. Journal article Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study (2018) Hirschfield G, Boudes P, Bowlus C, Gitlin N, Michael G, Harrison S, Gordon SC, et al. Conference contribution Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta Agonist, in Primary Biliary Cholangitis: 52-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 Study (2018) Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, Kremer A, et al. Conference contribution Effect of Seladelpar on Pruritus in Primary Biliary Cholangitis: 26-Week Analysis of an Ongoing International, randomized, Dose Ranging Phase 2 Study (2018) Kremer A, Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, et al. Conference contribution Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score (2018) Holtsche MM, Goletz S, Van Beek N, Zillikens D, Benoit S, Harman K, Walton S, et al. Journal article Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study (2017) Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, et al. Journal article Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02) (2017) Siegel CA, Lichtenstein G, Siegmund B, Lewis JD, Wolf D, Louis E, Sebastian S, et al. Conference contribution Doxycycline versus Prednisolone for the initial Treatment of bullous Pemphigoids: a pragmatic prospective randomized Study (2017) Schmidt E, Benoit S, Ehrchen J, Glaeser R, Guenther C, Steinbrink K, Sticherling M, et al. Conference contribution